Navigation Links
Long-term study: Robot-assisted prostate surgery is safe
Date:3/23/2011

In the first study of its kind, urologists and biostatisticians at Henry Ford Hospital have found that robot-assisted surgery to remove cancerous prostate glands is safe over the long term, with a major complication rate of less than one percent.

The findings, published online this month by the journal European Urology, follow an earlier Henry Ford study that found nearly 87 percent of patients whose cancerous prostates were removed by robot-assisted surgery had no recurrence of the disease after five years.

"We have always felt that robotic surgery for prostate cancer was safe, but there have been no studies that have looked at long-term safety. This is why the Henry Ford study is so important," says Mani Menon, M.D., director of Henry Ford's Vattikuti Urology Institute.

The new research analyzed the surgical outcomes of more than 3,000 consecutive patients at Henry Ford's Vattikuti Urology Institute from January 2005 to December 2009, and addressed "the lack of standardized reporting" that hampered previous published literature on complications of radical prostatectomy (RP).

In RP, the entire diseased prostate gland and some surrounding tissue are surgically removed, in hopes of preventing the cancer from spreading to other parts of the body.

Henry Ford Hospital pioneered the use of robots to assist surgeons in the delicate procedure, and the new study notes that robot-assisted radical prostatectomy (RARP) is now the most common technique in the U.S. for treating localized prostate cancer.

The Henry Ford researchers found only one previous report on complications of RP that had adhered to uniform surgical reporting standards. However that study looked at open and laparoscopic prostatectomy, and did not include robot-assisted RP.

Confronted, in a sense, by "apples and oranges" comparisons of several RP surgical techniques, the Henry Ford researchers set out to produce a five-year safety study that both concentrated on RARP and incorporated an exhaustive collection of data, covering everything from length of hospital stay, to an in-depth examination of other diseases afflicting the patients, but unrelated to their cancers.

Among the study group of 3,317 RARP patients, researchers found a median hospitalization time of only one day. There were 368 complications in 326 of the patients or 9.8 percent of the total most of which were minor and occurred within 30 days of the surgery.

A patient's prostate-specific antigen (PSA) scores before surgery, as well as cardiac disease, were found to predict medical complications after the robot-assisted surgery; age, gastroesophageal reflux disease (GERD), and biopsy score predicted possible surgical complications.

The researchers' main conclusion was that "RARP is a safe operation."

Henry Ford's robot-assisted urology program uses a surgeon-controlled robot, the da Vinci minimally invasive surgery system.

It enables surgeons to manipulate robotic arms for precise procedures through a series of small incisions, instead of the large wounds required by traditional "open" surgery, and provides 3-D monitoring for the entire surgical team.

The potential benefits for the patient include shorter recovery times, less trauma, and reduced hospitalization costs.

It is also the basis of a "nerve-sparing" procedure called the Veil of Aphrodite, developed at Ford, to minimize the erectile dysfunction common in men after undergoing traditional radical prostatectomy.

"While these results provide strong endorsement for robotic surgery, we want to emphasize that the results are dependent more on the surgical team that controls the da Vinci robot rather than just the robot," Dr. Menon states.


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Tamoxifen May Offer Long-Term Heart, Cancer Protection
2. Researchers find new mechanism behind the formation and maintenance of long-term memories
3. Herceptin May Boost Long-Term Survival After Aggressive Breast Cancer
4. Rituximab and fludarabine produce long-term remissions in CLL
5. Study links long-term use of osteoporosis drugs to unusual fractures
6. Facial Surgery May Offer Long-Term Migraine Relief for Some
7. Less radical tumor surgery can offer better long-term kidney function
8. Migraine surgery offers good long-term outcomes
9. Enhanced early childhood education pays long-term dividends in better health
10. More than 3,000 survivors of the WTC attacks experience long-term post-traumatic stress disorder
11. A decade of refinements in transplantation improves long-term survival of blood cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: